Modulating telomerase activity in tumor patients by targeting dyskerin binding site for hTR.
Telomeres shortening, which leads to apoptosis, is prevented by telomerase adding small repeated segments of DNA to the telomeres. The telomerase level has been correlated with progression of several cancer types, including acute leukemia, breast, prostate, lung cancer and melanoma. Suppression of telomerase activity was found to reduce metastatic potential but could have serious side effects in normal proliferative cells. One of the proteins stabilizing the telomerase complex called dyskerin reduces the maximum telomerase activity. We suggest a possible therapeutic agent which would disable the interaction of dyskerin and telomerase, but would not completely inhibit telomerase activity.